Progenity to Present at the 2021 ICR Conference
Progenity, Inc. (Nasdaq: PROG) will participate in the 2021 ICR Conference on January 14, 2021, at 4 p.m. ET. CEO Harry Stylli will present a company overview during the event. A live audio webcast will be accessible on Progenity's website, with an archived replay available post-event.
Progenity focuses on developing and commercializing molecular testing products and innovations in precision medicine, aiming to enhance healthcare through accurate diagnostics and targeted treatments.
- None.
- None.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced its participation in the 2021 ICR Conference. Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, will present a company overview on Thursday, January 14, 2021 at 4 p.m. ET (1 p.m. PT).
A live audio webcast of the presentation will be available in the Investors section of the company’s website at progenity.com/presentations, with an archived replay available following the event.
About Progenity
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For more information on how Progenity is helping clinicians and patients prepare for life, please visit www.progenity.com.
Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
ir@progenity.com
(619) 228-5886
Media Contact:
Kate Blom-Lowery
CG Life
media@progenity.com
(858) 457-2436
FAQ
When is Progenity's presentation at the 2021 ICR Conference?
Who will present on behalf of Progenity at the ICR Conference?
Where can I watch Progenity's presentation live?
What is Progenity's focus in the biotechnology industry?
What is the stock symbol for Progenity?
